** Cancer therapy developer Coeptis Therapeutics' COEP.O shares rise 2.3% to $11.15
** Co says it has licensed worldwide development and commercialization rights to cell therapy platform GEAR
** As part of the agreement with VyGen-Bio, Coeptis has formed a new majority-owned subsidiary, GEAR Therapeutics, to advance applications of the technology
** GEAR (Gene Edited Antibody Resistant) cell therapy platform modifies immune cells to effectively target and destroy cancer cells without being neutralized by antibodies taken during treatment
** Up to last close, COEP has risen 13.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。